The NEJ009 study is a recent phase III clinical trial investigating the efficacy of gefitinib alone versus gefitinib plus pemetrexed and carboplatin as the first-line therapy of EGFR mutation-positive patients with advanced NSCLC,18 and has received enormous attention since it was reported at the 2018 American Society of Clinical Oncology (ASCO). Here, EGFR is linked to non-small cell lung carcinoma.